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AbstrACt
Introduction The scale- up of antiretroviral therapy (ART) 
across sub- Saharan Africa (SSA) has reduced mortality so 
that increasing numbers of children with HIV (CWH) are 
surviving to adolescence. However, they experience a range 
of morbidities due to chronic HIV infection and its treatment. 
Impaired linear growth (stunting) is a common manifestation, 
affecting up to 50% of children. However, the effect of HIV 
on bone and muscle development during adolescent growth 
is not well characterised. Given the close link between 
pubertal timing and musculoskeletal development, any 
impairments in adolescence are likely to impact on future 
adult musculoskeletal health. We hypothesise that bone and 
muscle mass accrual in CWH is reduced, putting them at risk 
of reduced bone mineral density (BMD) and muscle function 
and increasing fracture risk. This study aims to determine the 
impact of HIV on BMD and muscle function in peripubertal 
children on ART in Zimbabwe.
Methods and analysis Children with (n=300) and 
without HIV (n=300), aged 8–16 years, established on ART, 
will be recruited into a frequency- matched prospective 
cohort study and compared. Musculoskeletal assessments 
including dual- energy X- ray absorptiometry, peripheral 
quantitative computed tomography, grip strength and 
standing long jump will be conducted at baseline and after 
1 year. Linear regression will be used to estimate mean 
size- adjusted bone density and Z- scores by HIV status 
(ie, total- body less- head bone mineral content for lean 
mass adjusted for height and lumbar spine bone mineral 
apparent density. The prevalence of low size- adjusted 
BMD (ie, Z- scores <−2) will also be determined.
Ethics and dissemination Ethical approval for this study 
has been granted by the Medical Research Council of 
Zimbabwe and the London School of Hygiene and Tropical 
Medicine Ethics Committee. Baseline and longitudinal 
analyses will be published in peer- reviewed journals and 
disseminated to research communities.
IntroduCtIon
Sub- Saharan Africa (SSA) disproportionally 
bears the burden of global HIV infection, 
with nearly 90% of the estimated 2.1 million 
children under 15 years of age living in SSA.1 
The global scale- up of antiretroviral therapy 
(ART) has dramatically improved survival of 
children with HIV (CWH).2 However, there 
is accumulating evidence that the growing 
number of these children are now reaching 
adolescence in SSA with multisystem chronic 
comorbidities associated with HIV infection 
and/or its treatment.3
Poor linear growth (ie, stunting) is one 
of the most common manifestations of peri-
natally (vertically) acquired HIV infection, 
affecting up to 50% of children.4 5 Linear 
growth is greatest in adolescence during the 
pubertal development period. Bone mass is 
thought to change throughout the life course 
strengths and limitations of this study
 ► This study will provide novel understanding of the 
effects of HIV on bone and muscle development in 
a large population of sub- Saharan African children 
living with HIV by using ‘gold standard’ size adjust-
ment methods for dual- energy X- ray absorptiometry 
(DXA), which are crucial for assessing a population 
with inherent size differences.
 ► Bone architecture measurement using peripheral 
quantitative computed tomography (pQCT) will pro-
vide understanding of trabecular and cortical bone 
geometry and strength in children with HIV (CWH).
 ► This study will generate new data for total body and 
lumbar spine DXA, tibial pQCT, hand grip strength 
and standing long jump for Zimbabwean children 
without HIV which will inform normative reference 
data.
 ► While the age range in this study, 8–16 years, will 
allow analysis of pubertal delay in CWH, the follow- 
up period is insufficient to determine the impact on 
attainment of peak bone mass which probably oc-
curs in the early 20s.
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Figure 1 Hypothesised changes in bone mass across the life course in HIV- infected and HIV- uninfected individuals.
and may be altered by HIV6 7 (figure 1). The majority of 
peak bone mass (PBM), the maximum amount of bone 
accrued by the end of skeletal maturation, is attained 
during adolescent growth; by age 18 years in women and 
age 20 years in men, 80% of PBM is attained.8 After PBM 
is reached, there is no net gain in bone mass. Therefore, 
PBM is the net reservoir of bone for later life, a key deter-
minant of adult bone mineral density (BMD) and conse-
quently of adult osteoporotic fracture risk.9 Linear growth 
is therefore intimately linked to skeletal development but 
how HIV infection affects bone development in peripu-
bertal SSA children is largely unknown. The prevalence 
of low BMD has been found to be higher in CWH than 
uninfected children in high- income and middle- income 
countries (7% in the USA,10 32% in Brazil11 and 24% 
in Thailand12) compared with 1% in children without 
HIV in the USA.10 No study has estimated the preva-
lence of low BMD in SSA, and the prevalence of and risk 
factors for low BMD in African CWH are not known.6 13 
It is important to highlight that the risk of poor bone 
accrual, reflected in low BMD measurements, is likely 
to be different in low- income countries compared with 
high- income countries due to factors such as malnutri-
tion and social deprivation, but critically due to delayed 
ART initiation. A recent meta- analysis has shown that the 
median age of ART initiation in North America is 1 year, 
compared with 8 years in SSA.14
The mechanisms by which HIV may lead to low size- 
adjusted BMD in children are not fully understood but are 
likely multifactorial, including HIV- associated factors (eg, 
ART drugs, HIV disease stage) and traditional risk factors 
(eg, hypogonadism, smoking, alcohol, low physical activity 
and vitamin D deficiency).15 HIV infection promotes 
systemic immune activation and production of inflam-
matory cytokines (eg, tumour necrosis factor α), which, 
in turn, promote increased bone resorption.16 ART initi-
ation, particularly with tenofovir (part of the first- line 
ART regimen in SSA), predicts an initial decline in BMD 
which stabilises after 2 years in adults.17 It is thought 
that tenofovir may cause renal proximal tubule toxicity, 
resulting in phosphate wasting and increased bone turn-
over.18 Although tenofovir and protease inhibitors have 
been associated with low BMD in adults,19 20 studies in 
children have shown inconsistent findings.21–23 Malnu-
trition, opportunistic infections and social deprivation 
may also impede musculoskeletal development. Reduced 
physical activity, associated with HIV,24 may also impair 
muscle development and limit impact loading to reduce 
osteocyte- mediated bone accrual.25 26 In adults, weak grip 
strength has been associated with increased falls and frac-
ture risk.27 Although muscle (lean) mass has also been 
shown to predict the magnitude of bone accrual during 
growth,28 few studies have compared muscle strength and 
function between children with and without HIV. Inter-
estingly, a small Canadian study showed deficits in muscle 
power in CWH.29
Another mechanism by which HIV may exert effects on 
BMD is through its effect on puberty. Even in the presence 
of ART, the onset of puberty is delayed by approximately 
a year in CWH in both high- income30 and low- income 
settings.31 Older age at ART initiation has been shown to 
be a significant risk factor for pubertal delay in Zimba-
bwean CWH.31 Pubertal delay in HIV may be mediated 
through nutritional deficiency, recurrent infection or 
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chronic immune activation disrupting hormonal regula-
tion.31 Delayed puberty may be advantageous for linear 
growth; spending more time in puberty may allow more 
time for skeletal growth.31 Conversely, delayed puberty has 
been shown in studies in high- income settings to be detri-
mental to bone mass accrual.32 33 However, the impact of 
pubertal delay on BMD in low- income countries remains 
unknown. Pubertal delay can be assessed objectively using 
hand radiographs. Analysis of the growth plate develop-
ment and fusion of long bones in the hands can accu-
rately quantify bone age, which is a measure of skeletal 
maturation. Bone age lagging behind chronological age 
reflects pubertal delay.34
BMD is commonly measured by dual- energy X- ray 
absorptiometry (DXA) as two- dimensional (areal) 
BMD; however, this is highly dependent on bone 
size.35 DXA underestimates areal bone density in 
short children, with smaller bones, and overestimates 
BMD in taller children, with bigger bones, despite 
the fact that they may have identical volumetric BMD. 
Size adjustment of DXA measures is therefore criti-
cally important in children with chronic diseases such 
as HIV, where smaller size due to poorer growth and 
delayed puberty may explain findings of lower BMD. 
The two ‘gold standard’ size- adjustment techniques 
chosen from the International Society for Clinical 
Densitometry are as follows: bone mineral apparent 
density at the lumbar spine (LS BMAD) and regres-
sion based total- body less- head (TBLH) bone mineral 
content (BMC) for lean mass adjusted for height 
(TBLH BMCLBM)36 Z- scores. As there are currently no 
published reference DXA data for child or adolescent 
populations in SSA, in this study we will use the best 
available data sets from high- income countries such as 
the UK36 to generate Z- scores.
Unlike DXA, peripheral quantitative computed tomog-
raphy (pQCT) takes into account bone size by directly 
measuring volumetric BMD. It has the additional advan-
tage of separately assessing trabecular and cortical bone 
compartments, providing information on bone architec-
ture. Furthermore, a range of bone strength indices, for 
example, strength stain index, validated against fracture 
risk can be calculated.37 38 In high- income countries, 
markedly abnormal trabecular and cortical architecture 
have been shown in adults with HIV,39 and abnormal bone 
architecture and impaired bone strength through to early 
adulthood have been shown in boys with HIV infection.39 
Few studies have assessed bone architecture and strength 
in CWH in SSA.
The IMVASK (IMpact of Vertical HIV infection on 
child and Adolescent Skeletal development in Harare, 
Zimbabwe) study aims to determine the prevalence of low 
size- adjusted BMD and muscle function (grip strength 
and standing long jump) in Zimbabwean children with 
and without HIV. pQCT assessment will enable under-
standing of the impact of HIV infection on bone archi-
tecture and strength. This study will further contribute 
to local reference data for DXA measures, bone age and 
muscle function (grip strength and standing long jump) 
for an SSA population, establishing a biorepository for 
future research. Study results will aid understanding of 
bone and muscle accrual in the context of HIV infection 
in the era of ART.
MEthods And AnAlysIs
study objectives
This study aims to determine the impact of HIV infection 
on size- adjusted bone density in peripubertal children 
aged 8–16 years established on ART. In addition, this 
prospective study aims:
1. To quantify the prevalence of low size- adjusted BMD 
and low muscle function (grip strength and standing 
long jump) among CWH compared with uninfected 
children.
2. To investigate the risk factors for low size- adjusted 
bone density and low muscle function (grip strength 
and standing long jump) among CHW.
3. To compare the rates of bone mass accrual over 1 year 
between children with and without HIV and assess for 
interaction by pubertal stage to determine if CWH ex-
hibit catch up growth.
4. To determine the differences in bone architecture 
measured by pQCT between children with and with-
out HIV.
study hypothesis
We hypothesise that HIV infection adversely affects skel-
etal development, such that CWH, despite ART, accrue 
less bone mass and strength and have reduced muscle 
function during skeletal development.
study design
CWH aged 8–16 years and established on ART 
(n=300) and a comparison group of children without 
HIV, frequency- matched for age and sex (n=300) will 
be recruited into a prospective cohort study. Detailed 
musculoskeletal assessments will be conducted at 
baseline and after 1 year.
study setting
Parirenyatwa and Harare Hospital are the largest 
public- sector referral hospitals in Harare.40 41 The 
paediatric HIV clinics at both hospitals provide HIV 
care to more than 2000 children. Although HIV care 
is increasingly decentralised to primary care level 
across the country, most children in Harare continue 
to receive care within HIV clinics in secondary 
healthcare facilities. Parirenyatwa hospital has a well- 
functioning radiology department which houses the 
University of Zimbabwe DXA and pQCT research 
unit and has access to private radiology services in 
the surrounding area. The hospital catchment areas 
have over 116 primary and 42 secondary government 
schools with an estimated 157 962 children enrolled.42 
School attendance in Harare province is high and 
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does not differ by HIV status, with 96% of children 
under 18 years attending school.43
recruitment of participants
Eligibility
Inclusion criteria: age 8–16 years (includes prepubertal 
and peripubertal children), living in Harare, and in CWH 
only if:
i. Taking ART for at least 2 years (as adult studies 
demonstrate ART initiation is followed by an initial 
decline in BMD which stabilises after 2 years).17
ii. The child is aware of their HIV status, to avoid inad-
vertent disclosure as a result of study participation.
Children with perinatally acquired HIV will be included 
in this study. Perinatally acquired HIV will be defined 
based on Zimbabwean criteria, that is, self- report of no 
sexual debut or blood transfusions, a history of natural 
sibling or maternal HIV and characteristic clinical 
features of longstanding HIV. Children with horizontal 
infection will also be included in the study.
Exclusion criteria: acute illness (requiring immediate 
hospitalisation) and lack of consent.
Detailed information on all the above comorbidities 
will be collected using the main study questionnaire in 
the clinical history section. This information will be 
collected for both children with and without HIV. Comor-
bidities will not be used as the basis of excluding children 
from the study. However, for the purposes of deriving 
normative DXA data, those with severe bone disease will 
be excluded at the analysis stage.
Recruitment of children with HIV
Systematic quota- based sampling by age and sex will 
be used to recruit 300 children from Parirenyatwa and 
Harare Hospital HIV clinics. Participants will be recruited 
sequentially as they attend clinic such that 50 male and 50 
female will be chosen for each of three age strata: 8–10.99, 
11–13.99 and 14–16.99 years. A maximum of five partici-
pants will be enrolled on each day for logistical reasons. 
The total number of children approached each day will 
be recorded, irrespective of whether they are subse-
quently eligible or enrolled to determine the sampling 
fraction. Written consent will be obtained from children 
and their guardians. Study processes and procedures will 
be clearly explained to children and their guardians and 
they will be given the option to accept or decline to take 
part in the research. It will also be explained that they are 
allowed to withdraw from the study at any time, for any 
reason, without affecting the care they receive from the 
clinic.
Recruitment of children without HIV
Three hundred CWH will be randomly sampled from 
six government primary and secondary schools in the 
same catchment area as Parirenyatwa and Harare Hospi-
tals. Younger children (8–12 years) will be selected from 
primary schools and older children (13–16 years) from 
secondary schools, with 13 year olds coming from both 
primary and secondary schools. The number of children 
selected from each school will be proportional to school 
size, thereby giving each child equal probability of being 
sampled. A random number sequence will be generated, 
and school registers will be used to select participants of 
similar age and sex as the children with HIV using the 
same quota- based approach of 50 male and 50 female in 
each of the three age strata. Guardians of selected school 
children will be invited to the study clinic to complete the 
consent process. Consenting participants will have a diag-
nostic HIV test as part of their assessment. Those testing 
HIV positive (anticipated to be approximately 2%–3%44) 
will be referred for HIV care.
study procedures
Questionnaire
An interviewer- administered questionnaire together with 
hand- held medical records will be used to collect sociode-
mographic details and clinical history including age, sex, 
school attendance, orphan status, guardianship, history 
of fractures with mechanism of trauma, steroid use, 
smoking, alcohol, recreational drugs, family history of 
musculoskeletal disease, comorbidities, physical activity, 
diet and nutrition, and sun exposure. Where possible, 
validated instruments adapted for the local context will 
be used. For example, the International Physical Activity 
Questionnaire (IPAQ)45 validated in multiple countries 
including South Africa and will be used to assess physical 
activity as multiples of the resting metabolic rate (MET) 
in MET- minutes. Diet and nutrition will be assessed using 
a tool we developed for the Zimbabwean context based 
on a validated dietary diversity and food frequency tool 
from India and Malawi46 and international guidelines 
applicable to SSA.47 The tool quantifies vitamin D supple-
mentation and sunlight exposure and has been adapted 
to reflect the Zimbabwean context where fortification of 
oils and margarine with vitamin D is mandated by the 
government and specific vitamin D–rich foods such as 
kapenta fish are found.
Clinical examination
A standardised musculoskeletal examination will be 
conducted using the validated paediatric Gait, Arms, 
Legs and Spine (pGALS) examination.48 Additional clin-
ical assessments will be carried out using standardised 
protocols and calibrated equipment. Anthropometry 
measurements will include standing and sitting height, 
arm span and mid- upper arm circumference. Height 
will be measured to the nearest 0.1 cm, by two separate 
readers using calibrated Seca 213 stadiometers. If the two 
height measurements differ by more than 0.5 cm, a third 
reading will be taken.49 Weight will be measured to the 
nearest 0.1 kg using calibrated Seca 875 scales. Tanner 
pubertal staging will be carried out using a standardised 
protocol with an orchidometer to assess testicular volume 
in male participants.50 Muscle function will be assessed in 
the upper and lower limbs by grip strength dynamometry 
and standing long jump, respectively. Hand grip strength 
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will be measured using a Jamar hydraulic hand- held dyna-
mometer (Patterson Medical, UK) to the nearest 0.1 kg. 
Participants will be seated with the shoulder at 0° to 10°, 
the elbow at 90° of flexion and the forearm positioned 
neutrally. Three measurements will be taken from each 
hand in alternation and the highest measurement chosen. 
The standing long jump distance will be taken from the 
best of three correctly performed attempts to the nearest 
0.1 cm, measuring the distance from the take- off line to 
the heel.
Radiological assessments
DXA scans will be performed by two trained radiogra-
phers using a Hologic QDR Wi densitometer with Apex 
software V.4.5. Measurements will be taken from the 
lumbar spine, hip and total body. Fat and muscle mass 
will also be acquired; muscle mass is the fat- free mass 
measurement from DXA. DXA scans will be repeated in 
a subgroup (n=20) of participants to determine repro-
ducibility. pQCT measurements of the non- dominant 
tibia will be taken using a Stratec XCT-2000 scanner 
(Stratec, Pforzheim, Germany) software V.6.20. Measure-
ments of the non- dominant tibia will be taken at three 
sites at 4%, 38% and 66% of the tibial length, measured 
from the medial malleolus to the medial tibial plateau. 
Daily quality control will be performed by scanning the 
manufacturer- provided lumbar spine phantom for DXA 
and tibia phantom for pQCT. A radiograph of the non- 
dominant hand and wrist will be taken and used to quan-
tify bone age using the Greulich and Pyle (G&P) atlas and 
the Tanner Whitehouse 3 (TW3) method. For intraob-
server reliability, 10% of the radiographs will be randomly 
selected and rescored by the same operator after 1 week. 
For interobserver reliability, a different set of 10% of the 
radiographs will be rescored by a different expert. The 
estimated bone age will then be compared with the calcu-
lated chronological age.
Blood tests
A fasting blood sample (up to 15 mL) will be collected. 
HIV markers (CD4 count and viral load) will be tested in 
CWH only. CD4 cell count will be measured using an Alere 
PIMA CD4 machine (Waltham, Massachusetts, USA). HIV 
viral load will be measured using the GeneXpert HIV-1 
viral load platform (Cepheid, Sunnyvale, California, 
USA). The remaining blood plasma will be biobanked to 
enable future measurement of bone biochemistry. After 
removing the plasma, peripheral blood mononuclear 
cells will be isolated and cryopreserved. DNA will also be 
extracted using a manual method and stored for future 
genetic studies.
Follow-up at 1 year
All study measurements, with the exception of DNA 
extraction, will be repeated after 1 year. Participants 
will be recalled exactly 1 year after their first DXA scan. 
The aim is to perform all scans within a 4- week window 
period. Contact will be maintained with participants 
via regular phone calls and text messaging to minimise 
loss- to- follow- up. The schedule of study procedures is 
summarised in table 1.
outcome measures
The primary study outcomes are as follows:
1. Mean size- adjusted bone density Z- scores; TBLH 
BMCLBM and LS BMAD.36
2. The prevalence of low TBLH BMCLBM and LS BMAD 
Z- score<−2 at baseline.36
Secondary study outcomes are as follows:
1. Prevalence of low muscle function; grip strength and 
standing long jump- for- age (Z- score<−2) and muscu-
loskeletal abnormalities/disabilities by HIV status at 
baseline.
2. Mean percentage change in TBLH BMCLBM (g) and LS 
BMAD (g/cm3), tibial cortical and trabecular volumet-
ric BMD (g/cm3), total cross sectional area, cortical 
thickness and bone strength, muscle mass and func-
tion at baseline and 1 year, by HIV status.
3. Assessment of the extent to which pubertal delay ex-
plains changes in these bone and muscle outcomes.
sample size
The sample size was calculated to detect differences in 
DXA- measured mean size- adjusted bone BMD Z- scores 
between children with and without HIV. This study will 
have 80% power (α 0.05) to detect a 0.23 Z- score differ-
ence between 300 HIV- infected and 300 uninfected 
children, assuming an SD of 1.3. As there were no 
published studies from low income countries, estimates 
of the expected difference were taken from a US study 
of children with HIV aged 7–15 years.10 In addition, our 
study will have 80% power to detect a 4.8% difference in 
the prevalence low size- adjusted BMD between the two 
groups. This is a smaller prevalence difference than that 
detected by the most conservative prevalence estimate of 
low BMD of 7% from three studies in high- income and 
middle- income countries.10–12
statistical analysis
For continuous variables that are normally distributed, 
the mean and SD will be presented. For skewed contin-
uous variables, the median and IQR will be presented. 
Categorical variables will be summarised as frequencies 
and percentages. The distribution of demographic and 
clinical variables will be compared between CWH and 
without HIV using independent sample t- tests for means, 
Wilcoxon rank- sum test for medians and χ2 tests for 
proportions.
Baseline mean TBLH BMCLBM and LS BMAD Z- scores 
and the prevalence of low TBLH BMCLBM and LS BMAD 
Z- score will be compared between CWH and without 
HIV. Among CWH, the association between a priori 
defined risk factors (ART duration, ART type, proportion 
of life on treatment, age at ART initiation, CD4 count, 
viral load, bone age, pubertal stage, nutrition, socio-
economic status and orphanhood) against size- adjusted 
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Figure 2 Hypothesised growth scenarios to be assessed as interactions between pubertal stage and HIV status on change in 
bone mass.
BMD will be examined using multivariable linear regres-
sion (Z- score as a continuous variable) and multivariable 
logistic regression (as defined by the Z- score cut- off of 
<−2). Successful antiretroviral therapy will be defined as 
a viral load of less than 1000 copies/mL. Paired sample 
t- test or non- parametric Wilcoxon test will be used to 
assess for differences in TBLH BMC and LS BMAD on 
children with and without HIV between baseline and 
follow- up. Multivariable linear regression will be used to 
analyse the mean percentage change in TBLH BMCLBM 
(g) and LS BMAD (g/cm3) between children with and 
without HIV. Models will be adjusted for physical activity, 
calcium and vitamin D intake. Interaction between the 
effects of pubertal stage (bone age) and HIV on change 
in TBLH BMCLBM and LS BMAD will be investigated to 
see if differences in bone density become more or less 
pronounced through puberty, that is, whether catch- up 
growth is possible, see figure 2. The regression coefficient 
(β) for percentage change in size- adjusted bone mass 
may suggest either no growth impairment (figure 2A), 
delayed puberty while maintaining the same growth 
trajectory (figure 2B) or delayed puberty with a reduced 
growth trajectory (figure 2C) in CWH. If β is markedly 
more positive in CWH, this suggests that catch- up growth 
may be possible (figure 2D). Pubertal delay in this study 
will be defined as the lack of the initial signs of puberty 
(Tanner stage 2) at an age that is more than 2 SD beyond 
the population mean51 and as chronological age minus 
bone age >2 years.52 Data for total body and lumbar spine 
DXA, tibial pQCT, hand grip strength and standing long 
jump in CWH will be analysed with reference to the 
comparator group of children without HIV.
For the purposes of normative data derivation, chil-
dren without HIV who have any diagnosis or evidence of 
muscle or bone disease will be excluded. Then outliers 
with bone density, hand grip strength or standing long 
jump data beyond 2 SD from the mean will have their 
case record reviewed to exclude cases with underlying 
bone or muscle pathology. The remaining population 
will be used to generate normative references ranges for 
these quantitative traits.
data management
Data collection, management and storage will be 
governed by standard operating procedures and will 
follow the principles of Good Clinical Practice (GCP). 
Data will be captured using hand- held tablets for the ques-
tionnaires. Paper forms will be available in case of failure 
of electronic data entry. Microsoft Access will be used as 
the main back- end database as it allows programming 
of quality control checks and conditional data valida-
tion. GCP compliant audit trail modules will be incorpo-
rated into the databases and reports of aggregated data 
will be reviewed on a monthly basis. In order to assure 
data quality and consistency, all staff will receive regular 
training and regular quality checks will be conducted. 
Paper records will be stored for 8 years after the comple-
tion of research in secure, locked storage facilities. Field 
staff will download data to the central database, which is 
backed up onto an encrypted external hard drive daily, 
and to additional off- site and secure cloud back- up. The 
off- site back- up copies will be stored through the London 
School of Hygiene and Tropical Medicine (LSHTM) 
Research Data Management Support Service that has an 
established data repository. In order to preserve the long- 
term value of these data, it will be stored backed- up here 
indefinitely. Anonymised research data will be made avail-
able for sharing through the open access data repository 
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established by the LSHTM Data Management Support 
Service at the time of publication. This will allow other 
research groups to request access to study data and tools. 
Information on other researchers’ data will be included 
in every study publication.
Patient and public involvement
While patients were not directly involved in the design 
and conduct of the study, feedback from patient expe-
riences in the study will be used to inform planned 
public engagement activities, which include science fairs, 
conducted by the research team at schools from where 
participants were recruited.
study status
Recruitment to this study began in May 2018 and is 
planned until August 2019. Study follow- up will run from 
May 2019 to August 2020.
dIsCussIon
Although the scale- up of prevention of mother- to- child 
transmission has reduced perinatal HIV transmission, 
coverage is still not universal in most parts of SSA and 
therefore perinatal HIV infection is expected to affect 
large numbers of children for years to come. Further-
more, the scale- up of ART has reduced HIV- associated 
mortality dramatically so that CWH, who would previ-
ously have died in infancy or early childhood, are now 
reaching adolescence in increasing numbers. It is there-
fore important to understand the impact of HIV infection 
and its treatment on skeletal development during the crit-
ical period of puberty.
This study will determine the prevalence of low size- 
adjusted BMD in children with and without HIV in 
Zimbabwe, a country with a severe sustained early onset 
HIV epidemic. In addition, this study will determine risk 
factors for low size- adjusted BMD in CWH. We aim to 
identify factors amenable to intervention, which may be 
modifiable to maximise future bone health and minimise 
subsequent adult osteoporotic fracture risk. For example, 
reduced muscle function predicting low size- adjusted 
BMD may suggest targeted physiotherapy would be of 
benefit, which would warrant formal investigation.
Our study will provide insights regarding the mech-
anisms through which perinatal HIV infection affects 
the timing of pubertal onset and bone mass accrual. By 
measuring bone and muscle parameters at baseline and 
1 year and by employing ‘gold standard’ size- adjustment 
methodology for DXA- measured BMD in the growing 
skeleton, this study will also provide insights into whether 
catch- up growth in terms of bone mass accrual is possible 
in HIV despite pubertal delay and provide age- related 
growth velocity data for CWH, with and without puberty.
While the age range in this study will allow analysis of 
pubertal delay in CWH, the follow- up period is insuffi-
cient to determine the impact on attainment of PBM, 
which probably occurs in the early 20s.8 In addition, this 
study is not sufficiently powered to analyse the effect of 
individual ART types on size- adjusted bone density. An 
additional limitation is the inability to obtain accurate 
height data for CWH prior to enrolment to fully study 
growth recovery. This is problematic given the signifi-
cant role of poverty and nutrition, independent of HIV 
status, in the first 1000 days of childhood53; this may 
explain some of the deficit in final height attained by 
CWH.
The bone architecture measured by pQCT in this 
study will provide separate assessments of trabecular and 
cortical bone density, and bone geometry and strength 
in Zimbabwean children. The evidence from studies in 
adult men established on ART demonstrates impairments 
in trabecular and cortical bone architecture.54 Whether 
the same applies to children needs to be determined.
Furthermore, we will establish novel comparator data 
for DXA, pQCT, bone age, hand grip strength and 
standing long jump for a Zimbabwean population, which 
will be used for future research in this context. Although 
this represents the first steps towards developing norma-
tive reference data, the extent to which the children 
without HIV infection in this study are representative of 
the Zimbabwean population of 8–16 year olds is unknown. 
Furthermore, this study will establish a biorepository for 
future research, for example, potential bone turnover 
marker measurement and genotyping.
Given the magnitude of the HIV epidemic in SSA and 
the large cohort of young people who may experience 
impaired bone accrual, musculoskeletal disability or frac-
ture as they reach adolescence and early adulthood, it is 
imperative to characterise the impact of perinatal HIV on 
musculoskeletal development.
EthICs And dIssEMInAtIon
Ethical approval has been granted by the LSHTM Ethics 
Committee (Ref: 15333; 14 May 2018), the Institutional 
Review Board of the Biomedical Research and Training 
Institute (Ref: AP 145/2018; 20 February 2018), the Joint 
Research Ethics Committee for University of Zimbabwe 
College of Health Sciences and the Parirenyatwa Group 
of Hospitals (JREC) (Ref: 11/18; 1 March 2018), Harare 
Central Hospital Ethics Committee (HCHEC) (Ref: 
170118/04; 23 February 2018), the Medical Research 
Council of Zimbabwe (Ref: MRCZ/A/2297; 10 April 
2018) and the Ministry of Primary and Secondary Educa-
tion Zimbabwe (Ref: C/426/Harare; 13 February 2018). 
This study is registered with the ISRCTN registry (Ref: 
ISRCTN12266984).
Study progress will be reported annually to MRCZ. 
Results of interim data analysis will be presented at 
national and international research meetings and confer-
ences. Study findings will be published in international 
peer- reviewed scientific journals and disseminated to 
research communities at the end of study.
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